Results 161 to 170 of about 272,686 (351)

Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction [PDF]

, 2017
Angiotensin II (All) has been implicated as an important factor in the pathophysiology of heart diseases. Following the recent identification of two subtypes of the All receptor in cardiac tissue of animals, we investigated the possible occurrence of ...
Burkart, F., de Gasparo, M., Eberhard, M., Erne, P., Graedel, E., Rogg, H., Stulz, P.   +6 more
core  

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain

Clinical Pharmacology &Therapeutics, EarlyView.
Pregabalin and duloxetine are widely prescribed non‐opioid medications for chronic musculoskeletal pain. Pregabalin may increase the risk of heart failure, and duloxetine increases heart rate and blood pressure; however, little is known about their comparative cardiovascular safety.
Sachalee Campbell, Puran Nepal, Laura Daniel, Otis Wilson, Alyson L. Dickson, Jennifer Maizel, Katherine T. Murray, William D. Dupont, Adriana Hung, Wayne A. Ray, C. Michael Stein, Cecilia P. Chung   +11 more
wiley   +1 more source

Angiotensin II type 1 receptor (AGTR1) [PDF]

Science-Business eXchange, 2011
openaire   +3 more sources

Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states

Nature Medicine, 2007
R. Cohn, C. V. Erp, J. Habashi, A. Soleimani, E. C. Klein, Matthew T. Lisi, Matthew Gamradt, C. Rhys, Tammy M. Holm, B. Loeys, F. Ramirez, D. Judge, C. Ward, H. Dietz   +13 more
semanticscholar   +1 more source

Studies on the structure-function relationship of angiotensin II type 1 receptor [PDF]

, 1996
Angiotensin II(Ang II), a biologically active peptide in the reninangiotensin system (RAS), plays an important role in the maintenance of blood pressure and fluid osmolarity[1,2,3].
Shibata Takeshi
core  

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

New England Journal of Medicine, 2005
D. Dragun, D. Müller, J. Bräsen, L. Fritsche, M. Nieminen-Kelhä, R. Dechend, U. Kintscher, B. Rudolph, J. Hoebeke, D. Eckert, I. Mazák, R. Plehm, C. Schönemann, T. Unger, K. Budde, H. Neumayer, F. Luft, G. Wallukat   +17 more
semanticscholar   +2 more sources

Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension.

HYPERTENSION, 1994
A. Bonnardeaux, E. Davies, X. Jeunemaître, I. Féry, A. Charru, E. Clauser, L. Tiret, F. Cambien, P. Corvol, F. Soubrier   +9 more
semanticscholar   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source